Providing sponsors expert staff to accelerate milestones and support study success
Acquires Swiss-based multi-disciplinary consultancy SFL (Solutions for Life Sciences) to accelerate the development of and access to innovative treatments
Accomplished Financial Executive to Drive Company’s Next Phase of Growth
Bridging the Gap between Trial and Treatment by Supporting the Approval of Several Novel Therapies for Rare Diseases
Acquires Drug Development and Regulation (DDR), a
regulatory consultancy led by former senior officer at
European Medicines Agency (EMA)
Global Talent Executive to Advance Company’s Commitment to a
Best-in-class Workforce
Recapitalization Will Accelerate Strategic Growth to Help Sponsors Save and Improve the Lives of Patients
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry during the Week of Rare Disease Day 2021
Veristat Supported the NDA and Celebrates this Milestone Achievement for Children and their Families Fighting This Rare Disease
SOUTHBOROUGH, MA – 8 March 2021 –Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021.
Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials
SOUTHBOROUGH, MA – February 25, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion of its biometrics capacities by acquiring SQN Clinical, a market-leader in the healthcare arena and one of the largest data focused specialty contract research companies in Europe.
Strengthening its Track Record of Successful Client Regulatory Approval Outcomes
SOUTHBOROUGH, MA – January 14, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)[i], and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe.